vs
Side-by-side financial comparison of AstroNova, Inc. (ALOT) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
AstroNova, Inc. is the larger business by last-quarter revenue ($39.2M vs $20.6M, roughly 1.9× Entrada Therapeutics, Inc.). AstroNova, Inc. runs the higher net margin — 1.0% vs -84.4%, a 85.4% gap on every dollar of revenue. On growth, AstroNova, Inc. posted the faster year-over-year revenue change (-3.4% vs -65.2%). AstroNova, Inc. produced more free cash flow last quarter ($3.3M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs 2.1%).
AstroNova, Inc. is a global technology firm designing, manufacturing and distributing specialty data visualization products, including high-performance label printers, test and measurement equipment, and aerospace-grade data recording systems, serving aerospace, manufacturing, retail and healthcare markets worldwide.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
ALOT vs TRDA — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.2M | $20.6M |
| Net Profit | $378.0K | $-17.3M |
| Gross Margin | 36.2% | — |
| Operating Margin | 3.3% | -106.0% |
| Net Margin | 1.0% | -84.4% |
| Revenue YoY | -3.4% | -65.2% |
| Net Profit YoY | 221.5% | -173.8% |
| EPS (diluted) | $0.05 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $39.2M | — | ||
| Q3 25 | $36.1M | — | ||
| Q2 25 | $37.7M | — | ||
| Q1 25 | — | $20.6M | ||
| Q4 24 | $40.4M | $37.4M | ||
| Q3 24 | $40.5M | $19.6M | ||
| Q2 24 | $33.0M | $94.7M | ||
| Q1 24 | $39.6M | $59.1M |
| Q4 25 | $378.0K | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-376.0K | — | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | $240.0K | $1.1M | ||
| Q3 24 | $-311.0K | $-14.0M | ||
| Q2 24 | $1.2M | $55.0M | ||
| Q1 24 | $2.7M | $23.5M |
| Q4 25 | 36.2% | — | ||
| Q3 25 | 32.2% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 35.3% | — | ||
| Q2 24 | 36.3% | — | ||
| Q1 24 | 31.9% | — |
| Q4 25 | 3.3% | — | ||
| Q3 25 | -2.0% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | — | -106.0% | ||
| Q4 24 | 3.1% | -15.7% | ||
| Q3 24 | 2.6% | -110.7% | ||
| Q2 24 | 4.1% | 56.4% | ||
| Q1 24 | 9.9% | 35.7% |
| Q4 25 | 1.0% | — | ||
| Q3 25 | -3.4% | — | ||
| Q2 25 | -1.0% | — | ||
| Q1 25 | — | -84.4% | ||
| Q4 24 | 0.6% | 3.0% | ||
| Q3 24 | -0.8% | -71.7% | ||
| Q2 24 | 3.6% | 58.1% | ||
| Q1 24 | 6.8% | 39.7% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | — | $-0.42 | ||
| Q4 24 | $0.03 | $-0.20 | ||
| Q3 24 | $-0.04 | $-0.35 | ||
| Q2 24 | $0.15 | $1.55 | ||
| Q1 24 | $0.37 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $76.9M | $417.3M |
| Total Assets | $140.8M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6M | — | ||
| Q3 25 | $3.9M | — | ||
| Q2 25 | $5.4M | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | $4.4M | $101.2M | ||
| Q3 24 | $4.8M | $78.0M | ||
| Q2 24 | $4.0M | $185.3M | ||
| Q1 24 | $4.5M | $68.4M |
| Q4 25 | $76.9M | — | ||
| Q3 25 | $75.8M | — | ||
| Q2 25 | $76.6M | — | ||
| Q1 25 | — | $417.3M | ||
| Q4 24 | $92.2M | $428.7M | ||
| Q3 24 | $91.8M | $422.4M | ||
| Q2 24 | $91.2M | $429.9M | ||
| Q1 24 | $90.3M | $269.4M |
| Q4 25 | $140.8M | — | ||
| Q3 25 | $143.1M | — | ||
| Q2 25 | $150.3M | — | ||
| Q1 25 | — | $486.5M | ||
| Q4 24 | $166.5M | $526.3M | ||
| Q3 24 | $169.0M | $554.6M | ||
| Q2 24 | $126.6M | $582.0M | ||
| Q1 24 | $133.3M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.4M | $-38.5M |
| Free Cash FlowOCF − Capex | $3.3M | $-39.7M |
| FCF MarginFCF / Revenue | 8.5% | -192.9% |
| Capex IntensityCapex / Revenue | 0.2% | 5.6% |
| Cash ConversionOCF / Net Profit | 9.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.9M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.4M | — | ||
| Q3 25 | $249.0K | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | — | $-38.5M | ||
| Q4 24 | $-4.7M | $-31.6M | ||
| Q3 24 | $162.0K | $-24.3M | ||
| Q2 24 | $6.9M | $39.8M | ||
| Q1 24 | $6.5M | $-25.5M |
| Q4 25 | $3.3M | — | ||
| Q3 25 | $202.0K | — | ||
| Q2 25 | $4.3M | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | $-5.0M | $-32.2M | ||
| Q3 24 | $-176.0K | $-24.9M | ||
| Q2 24 | $6.4M | $38.8M | ||
| Q1 24 | $6.0M | $-26.4M |
| Q4 25 | 8.5% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 11.5% | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | -12.4% | -86.2% | ||
| Q3 24 | -0.4% | -127.3% | ||
| Q2 24 | 19.5% | 41.0% | ||
| Q1 24 | 15.3% | -44.6% |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | 0.6% | 1.7% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 1.5% | 1.1% | ||
| Q1 24 | 1.0% | 1.4% |
| Q4 25 | 9.05× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -19.76× | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.85× | 0.72× | ||
| Q1 24 | 2.38× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALOT
| Public Utilities Inventory Supplies | $20.6M | 53% |
| Hardware Products | $12.7M | 32% |
| Service And Other | $5.9M | 15% |
TRDA
Segment breakdown not available.
